Recombinant Osteoprotegerin protein (ab110188)

Overview

Description

  • NatureRecombinant
  • SourceYeast
  • Amino Acid Sequence
    • SequenceMETFPPKYLH YDEETSHQLL CDKCPPGTYL KQHCTAKWKT VCAPCPDHYY TDSWHTSDEC LYCSPVCKEL QYVKQECNRT HNRVCECKEG RYLEIEFCLK HRSCPPGFGV VQAGTPERNT VCKRCPDGFF SNETSSKAPC RKHTNCSVFG LLLTQKGNAT HDNICSGNSE STQK

Associated products

Specifications

Our Abpromise guarantee covers the use of ab110188 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • Applications

    Functional Studies

    SDS-PAGE

    Blocking - Blocking peptide for Anti-Osteoprotegerin antibody (ab9986)

  • Endotoxin level< 0.100 Eu/µg
  • FormLyophilised
  • Concentration information loading...

Preparation and Storage

  • Stability and Storage

    Shipped at 4°C. The lyophilized protein is stable for a few weeks at room temperature. Store at -20°C or -80°C. Avoid freeze / thaw cycle. Please see notes section.

  • ReconstitutionCentrifuge the vial prior to opening. Reconstitute in 5 mM Tris, pH 7.5 to a concentration of 0.1-1.0 mg/ml. Do not vortex. This solution can be stored at 2-8oC for up to 1 week. For extended storage, it is recommended to further dilute in a buffer containing a carrier protein (example 0.1% BSA) and store in working aliquots at -20oC to -80o C.

General Info

  • Alternative names
    • MGC29565
    • OCIF
    • OPG
    • Osteoclastogenesis inhibitory factor
    • Osteoprotegerin
    • PDB5
    • TNF receptor superfamily member 11b
    • TNFRSF 11B
    • TNFRSF11B
    • TR 1
    • TR1
    • TR11B_HUMAN
    • Tumor necrosis factor receptor superfamily member 11B
    see all
  • FunctionActs as decoy receptor for RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local RANKL/OPG ratio. May also play a role in preventing arterial calcification. May act as decoy receptor for TRAIL and protect against apoptosis. TRAIL binding blocks the inhibition of osteoclastogenesis.
  • Tissue specificityHighly expressed in adult lung, heart, kidney, liver, spleen, thymus, prostate, ovary, small intestine, thyroid, lymph node, trachea, adrenal gland, testis, and bone marrow. Detected at very low levels in brain, placenta and skeletal muscle. Highly expressed in fetal kidney, liver and lung.
  • Involvement in diseaseDefects in TNFRSF11B are the cause of juvenile Paget disease (JPD) [MIM:239000]; also known as hyperostosis corticalis deformans juvenilis or hereditary hyperphosphatasia or chronic congenital idiopathic hyperphosphatasia. JPD is a rare autosomal recessive osteopathy that presents in infancy or early childhood. The disorder is characterized by rapidly remodeling woven bone, osteopenia, debilitating fractures, and deformities due to a markedly accelerated rate of bone remodeling throughout the skeleton. Approximately 40 cases of JPD have been reported worldwide. Unless it is treated with drugs that block osteoclast-mediated skeletal resorption, the disease can be fatal.
  • Sequence similaritiesContains 2 death domains.
    Contains 4 TNFR-Cys repeats.
  • Post-translational
    modifications
    N-glycosylated. Contains sialic acid residues.
    The N-terminus is blocked.
  • Cellular localizationSecreted.
  • Information by UniProt

References for Recombinant Osteoprotegerin protein (ab110188)

ab110188 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab110188.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"